Research Analysts Offer Predictions for ASMB Q1 Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Assembly Biosciences in a research note issued to investors on Thursday, March 26th. HC Wainwright analyst P. Trucchio forecasts that the biopharmaceutical company will post earnings of ($0.16) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q2 2027 earnings at ($1.13) EPS, Q3 2027 earnings at ($1.10) EPS, Q4 2027 earnings at $1.67 EPS and FY2030 earnings at $3.23 EPS.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The firm had revenue of $42.47 million during the quarter, compared to analyst estimates of $7.42 million.

Several other analysts have also recently weighed in on ASMB. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.75.

Assembly Biosciences Price Performance

Shares of ASMB stock opened at $27.70 on Friday. The firm’s 50-day moving average is $27.93 and its two-hundred day moving average is $29.79. Assembly Biosciences has a 12 month low of $7.75 and a 12 month high of $39.71. The company has a market capitalization of $439.41 million, a PE ratio of -37.43 and a beta of 1.11.

Institutional Investors Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares during the period. Seven Fleet Capital Management LP purchased a new stake in shares of Assembly Biosciences during the fourth quarter worth $147,000. Acadian Asset Management LLC increased its position in shares of Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,823 shares during the period. Charles Schwab Investment Management Inc. acquired a new stake in shares of Assembly Biosciences in the fourth quarter valued at $228,000. Finally, Virtus Investment Advisers LLC acquired a new stake in shares of Assembly Biosciences in the fourth quarter valued at $251,000. 19.92% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences News Roundup

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $50 target, which supports investor upside expectations. Article Title
• Positive Sentiment: The firm raised FY2026 estimates sharply (to $1.61 EPS) and put a large $3.51 EPS estimate for Q4‑2026 — signals HC Wainwright sees material near‑term revenue/earnings drivers that could deliver a positive earnings surprise in late 2026.
• Positive Sentiment: HC Wainwright also raised FY2028 estimates (to $0.32 EPS), suggesting a view that Assembly’s longer‑term pipeline/commercial prospects can generate positive earnings beyond the immediate quarters.
• Neutral Sentiment: The report includes a suite of multi‑year projections (Q1–Q4 2027, FY2030 estimates such as $3.23 EPS for FY2030) that provide modeling guidance but are farther out and carry higher uncertainty for near‑term stock moves.
• Negative Sentiment: HC Wainwright cut Q1, Q2 and Q3 2026 estimates (to roughly ($0.73), ($0.71), ($0.69) EPS respectively), indicating weaker expected near‑term performance that can pressure the stock until the company shows improving quarterly results.
• Negative Sentiment: The firm lowered FY2027 and FY2029 forecasts materially (FY2027 to ($0.64) from $1.44; FY2029 to ($2.83) from $3.09), pointing to increased downside risk in certain outyears and greater forecast volatility that can weigh on sentiment.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.